Clinical characteristics, outcome and the role of viral load in nontransplant patients with Epstein-Barr viraemia

Clinical Microbiology and Infection

Volumn 16, Issue 6, 2010, Pages 657-662

  Martelius, T ^a   Lappalainen, M ^b   Aalto, S M ^c   Nihtinen, A ^b   Hedman, K ^b   Anttila, V J ^a  

^a Department of Medicine   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c Department of Virology ^*  (Finland)

Author keywords

Epstein Barr virus; Hospital; Immunosuppression; PCR

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; FLUDARABINE; MERCAPTOPURINE; RITUXIMAB; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE HEPATITIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CD4 LYMPHOCYTE COUNT; CELIAC DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CROHN DISEASE; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NK T CELL LYMPHOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROLYMPHOCYTIC LEUKEMIA; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME; T CELL LYMPHOMA; VIREMIA; VIRUS LOAD;

HUMAN HERPESVIRUS 4;

EID: 77953948943     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02922.x     Document Type: Article

References (14)

1. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000, 343:481-492.
2. Aalto SM, Juvonen E, Tarkkanen J. Epstein-Barr viral load and disease prediction in a large cohort of allogeneic stem cell transplant recipients. Clin Infect Dis 2007, 45:1305-1309.
3. Smets F, Latinne D, Bazin H. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002, 73:1603-1610.
4. Wagner HJ, Wessel M, Jabs W. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001, 72:1012-1019.
5. Lin JC, Wang WY, Chen KY. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004, 350:2461-2470.
6. Gandhi MK, Lambley E, Burrows J. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res 2006, 12:460-464.
7. Aalto SM, Linnavuori K, Peltola H. Immunoreactivation of Epstein-Barr virus due to cytomegalovirus primary infection. J Med Virol 1998, 56:186-191.
8. Loginov R, Aalto S, Piiparinen H. Monitoring of EBV-DNAemia by quantitative real-time PCR after adult liver transplantation. J Clin Virol 2006, 37:104-108.
9. Aalto SM, Juvonen E, Tarkkanen J. Lymphoproliferative disease after allogeneic stem cell transplantation--pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum. J Clin Virol 2003, 28:275-283.
10. Kimura H, Morita M, Yabuta Y. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999, 37:132-136.
11. Balfour HH, Holman CJ, Hokanson KM. A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis 2005, 192:1505-1512.
12. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007, 25:587-617.
13. Morrison VA. Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2007, 2007:332-338.
14. Chan KC, Zhang J, Chan AT. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003, 63:2028-2032.